Ameriprise
ONCT

Ameriprise’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

Ameriprise’s Portfolio ONCT Stock Details ONCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-896
Closed -$16K – 4075
2022
Q3 		$16K Sell
896
-475
-35% -$10.2K ﹤0.01% 3927
2022
Q2 		$30K Sell
1,371
-433
-24% -$9.65K ﹤0.01% 3844
2022
Q1 		$50K Sell
1,804
-241
-12% -$8.77K ﹤0.01% 3877
2021
Q4 		$93K Sell
2,045
-1,058
-34% -$71.2K ﹤0.01% 3876
2021
Q3 		$259K Sell
3,103
-283
-8% -$23.4K ﹤0.01% 3632
2021
Q2 		$322K Sell
3,386
-18,375
-84% -$2.18M ﹤0.01% 3614
2021
Q1 		$3.62M Buy
+21,761
New +$2.88M ﹤0.01% 2585
2014
Q2 		– Sell
-15
Closed -$32K – 5676
2014
Q1 		$32K Sell
15
-88
-85% -$219K ﹤0.01% 3978
2013
Q4 		$239K Sell
103
-6
-6% -$13.7K ﹤0.01% 3082
2013
Q3 		$307K Buy
109
+108
+10,800% +$537K ﹤0.01% 3022
2013
Q2 		$12K Buy
+1
New +$7.71K ﹤0.01% 4658

Other funds holding ONCT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
QPW
Quantum Private Wealth Tampa, Florida $390M AUM 58.18% 1-Year Est. Return
BC
BIT Capital Berlin, Germany $2.07B AUM 157.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $2.37B AUM 16.36% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Ameriprise's ONCT Position: Q4 2022 in Review

Ameriprise sold out of Oncternal Therapeutics, Inc. Common Stock (ONCT) in Q4 2022, closing a stake of 896 shares — an estimated $16K sold.

Ameriprise first reported a position in ONCT in Q2 2013 and held it in 11 quarters. The position peaked at $3.62M in Q1 2021. 58 funds tracked by Wall St. Rank hold ONCT as of Q4 2022.

  • Ameriprise reported no remaining Oncternal Therapeutics, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • Ameriprise sold 896 Oncternal Therapeutics, Inc. Common Stock shares in Q4 2022, an estimated $16K.
  • Ameriprise first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q2 2013 and held it in 11 quarters.
  • Ameriprise's Oncternal Therapeutics, Inc. Common Stock position peaked at $3.62M in Q1 2021.
  • 58 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q4 2022.

Based on Ameriprise's 13F filing for Q4 2022, filed 14 Feb 2023.